Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 1/2012

01.01.2012 | Gynecologic Oncology

Lymphadenectomy as a prognostic marker in uterine non-endometrioid carcinoma

verfasst von: Ioannis Mylonas, Christian Schindlbeck

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Introduction

A pelvic lymphadenectomy with or without para-aortic lymphadenectomy is performed during surgery for endometrial cancer at least in high-risk patients for recurrence or progression. The question of whether pelvic and/or para-aortic lymphadenectomy improves survival rates of high-risk patients with uterine non-endometrioid carcinoma is still unclear. Therefore, the aim of this study was to evaluate the outcome of patients with uterine non-endometrioid cancer, with regard to the performance of a lymphadenectomy in a well-characterized cohort population.

Materials and methods

The prognostic value of a performed lymphadenectomy was examined in 55 patients with a histological diagnosis of a uterine non-endometrioid carcinoma. A performed lymphadenectomy was analyzed with respect to the surgical and pathological stage and characteristics.

Results

Of the 55 patients with an uterine non-endometrioid carcinoma, 38 (69.1%) and 2 (3.6%) patients were diagnosed in FIGO stage I and II, respectively, while 14 (25.5%) patients had FIGO stage III and 1 patient (1.8%) presented with metastatic disease (FIGO IV). 16 patients (29.1%) demonstrated a myometrial invasion of more than 50%, while a cervical and ovarian involvement could be observed in 7 (12.7%) and 9 (16.4%) cases, respectively. Pelvic and/or para-aortic lymph node sampling was performed for 42 patients (76.4%) while 7 patients (12.7%) demonstrated lymph node metastasis. Univariate survival analysis demonstrated no differences in progression-free survival, cause-specific survival or overall survival for a performed lymphadenectomy. Regression analysis led to a model containing only the FIGO surgical stage as an independent term that was predictive of progression-free survival, cause-specific survival and overall survival.

Discussion

Although a performed lymphadenectomy did not have any positive benefit in the survival of patients with uterine non-endometrioid carcinomas in this study, it might provide important prognostic information with a subsequent adjuvant treatment. However, these results remain to be confirmed in further larger and prospective studies.
Literatur
2.
Zurück zum Zitat Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I (2005) Endometrial cancer. Lancet 366:491–505PubMedCrossRef Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I (2005) Endometrial cancer. Lancet 366:491–505PubMedCrossRef
3.
Zurück zum Zitat Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK (2003) Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8:541–552PubMedCrossRef Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK (2003) Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8:541–552PubMedCrossRef
4.
Zurück zum Zitat Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E, Beerman H, van Lent M (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355:1404–1411. doi:S0140673600021395 PubMedCrossRef Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E, Beerman H, van Lent M (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355:1404–1411. doi:S014067360002139​5 PubMedCrossRef
5.
Zurück zum Zitat Papanikolaou A, Kalogiannidis I, Goutzioulis M, Misailidou D, Makedos A, Vergote I, Makedos G (2006) Pelvic lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer. Arch Gynecol Obstet 274:91–96. doi:10.1007/s00404-006-0138-y PubMedCrossRef Papanikolaou A, Kalogiannidis I, Goutzioulis M, Misailidou D, Makedos A, Vergote I, Makedos G (2006) Pelvic lymphadenectomy as alternative to postoperative radiotherapy in high risk early stage endometrial cancer. Arch Gynecol Obstet 274:91–96. doi:10.​1007/​s00404-006-0138-y PubMedCrossRef
6.
7.
Zurück zum Zitat Deligdisch L, Holinka CF (1987) Endometrial carcinoma: two diseases? Cancer Detect Prev 10:237–246PubMed Deligdisch L, Holinka CF (1987) Endometrial carcinoma: two diseases? Cancer Detect Prev 10:237–246PubMed
8.
9.
Zurück zum Zitat Lax SF (2004) Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444:213–223PubMedCrossRef Lax SF (2004) Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444:213–223PubMedCrossRef
10.
Zurück zum Zitat Jereczek-Fossa B, Badzio A, Jassem J (1999) Surgery followed by radiotherapy in endometrial cancer: analysis of survival and patterns of failure. Int J Gynecol Cancer 9:285–294PubMedCrossRef Jereczek-Fossa B, Badzio A, Jassem J (1999) Surgery followed by radiotherapy in endometrial cancer: analysis of survival and patterns of failure. Int J Gynecol Cancer 9:285–294PubMedCrossRef
11.
Zurück zum Zitat Faratian D, Stillie A, Busby-Earle RM, Cowie VJ, Monaghan H (2006) A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome. Int J Gynecol Cancer 16:972–978PubMedCrossRef Faratian D, Stillie A, Busby-Earle RM, Cowie VJ, Monaghan H (2006) A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome. Int J Gynecol Cancer 16:972–978PubMedCrossRef
12.
Zurück zum Zitat Dallenbach-Hellweg G (1999) Histopathologie und Stadieneinteilung des Endometriumkarzinoms inklusive seiner Präkanzerosen. Onkologe 5:388–395CrossRef Dallenbach-Hellweg G (1999) Histopathologie und Stadieneinteilung des Endometriumkarzinoms inklusive seiner Präkanzerosen. Onkologe 5:388–395CrossRef
13.
Zurück zum Zitat Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB (1987) Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 60:2035–2041PubMedCrossRef Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB (1987) Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 60:2035–2041PubMedCrossRef
14.
Zurück zum Zitat Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104PubMedCrossRef Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–104PubMedCrossRef
15.
Zurück zum Zitat (1989) FIGO stages (announcements). Gynecol Oncol 35:125–127 (1989) FIGO stages (announcements). Gynecol Oncol 35:125–127
16.
Zurück zum Zitat Soliman PT, Frumovitz M, Spannuth W, Greer MJ, Sharma S, Schmeler KM, Ramirez PT, Levenback CF, Ramondetta LM (2010) Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists. Gynecol Oncol 119:291–294. doi:10.1016/j.ygyno.2010.07.011 PubMedCrossRef Soliman PT, Frumovitz M, Spannuth W, Greer MJ, Sharma S, Schmeler KM, Ramirez PT, Levenback CF, Ramondetta LM (2010) Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists. Gynecol Oncol 119:291–294. doi:10.​1016/​j.​ygyno.​2010.​07.​011 PubMedCrossRef
17.
Zurück zum Zitat Sehouli J, Camara O, Stengel D, Kohler G, Lichtenegger W (2003) Multi-institutional survey on the value of lymphadenectomy in endometrial carcinoma in Germany. Gynakol Geburtshilfliche Rundsch 43:104–110PubMedCrossRef Sehouli J, Camara O, Stengel D, Kohler G, Lichtenegger W (2003) Multi-institutional survey on the value of lymphadenectomy in endometrial carcinoma in Germany. Gynakol Geburtshilfliche Rundsch 43:104–110PubMedCrossRef
18.
Zurück zum Zitat Bassarak N, Blankenstein T, Bruning A, Dian D, Bergauer F, Friese K, Mylonas I (2010) Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium? BMC Cancer 10:224. doi:10.1186/1471-2407-10-224 PubMedCrossRef Bassarak N, Blankenstein T, Bruning A, Dian D, Bergauer F, Friese K, Mylonas I (2010) Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium? BMC Cancer 10:224. doi:10.​1186/​1471-2407-10-224 PubMedCrossRef
19.
Zurück zum Zitat Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F 3rd, Conner W (1995) Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 56:29–33PubMedCrossRef Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F 3rd, Conner W (1995) Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 56:29–33PubMedCrossRef
20.
Zurück zum Zitat Orr JW Jr, Holimon JL, Orr PF (1997) Stage I corpus cancer: is teletherapy necessary? Am J Obstet Gynecol 176:777–788 (discussion 788-779)PubMedCrossRef Orr JW Jr, Holimon JL, Orr PF (1997) Stage I corpus cancer: is teletherapy necessary? Am J Obstet Gynecol 176:777–788 (discussion 788-779)PubMedCrossRef
21.
Zurück zum Zitat Ceccaroni M, Savelli L, Bovicelli A, Alboni C, Ceccarini M, Farina A, Bovicelli L (2004) Prognostic value of pelvic lymphadenectomy in surgical treatment of apparent stage I endometrial cancer. Anticancer Res 24:2073–2078PubMed Ceccaroni M, Savelli L, Bovicelli A, Alboni C, Ceccarini M, Farina A, Bovicelli L (2004) Prognostic value of pelvic lymphadenectomy in surgical treatment of apparent stage I endometrial cancer. Anticancer Res 24:2073–2078PubMed
23.
Zurück zum Zitat Lutman CV, Havrilesky LJ, Cragun JM, Secord AA, Calingaert B, Berchuck A, Clarke-Pearson DL, Soper JT (2006) Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol 102:92–97PubMedCrossRef Lutman CV, Havrilesky LJ, Cragun JM, Secord AA, Calingaert B, Berchuck A, Clarke-Pearson DL, Soper JT (2006) Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol 102:92–97PubMedCrossRef
24.
Zurück zum Zitat Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A (2005) Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 23:3668–3675PubMedCrossRef Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, Clarke-Pearson DL, Berchuck A (2005) Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 23:3668–3675PubMedCrossRef
26.
Zurück zum Zitat Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, Angioli R, Tateo S, Mangili G, Katsaros D, Garozzo G, Campagnutta E, Donadello N, Greggi S, Melpignano M, Raspagliesi F, Ragni N, Cormio G, Grassi R, Franchi M, Giannarelli D, Fossati R, Torri V, Amoroso M, Croce C, Mangioni C (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716. doi:10.1093/jnci/djn397 PubMedCrossRef Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, Angioli R, Tateo S, Mangili G, Katsaros D, Garozzo G, Campagnutta E, Donadello N, Greggi S, Melpignano M, Raspagliesi F, Ragni N, Cormio G, Grassi R, Franchi M, Giannarelli D, Fossati R, Torri V, Amoroso M, Croce C, Mangioni C (2008) Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716. doi:10.​1093/​jnci/​djn397 PubMedCrossRef
28.
Zurück zum Zitat Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, Jeschke U, Friese K, Mylonas I (2007) Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 43:2434–2444. doi:10.1016/j.ejca.2007.08.014 PubMedCrossRef Shabani N, Kuhn C, Kunze S, Schulze S, Mayr D, Dian D, Gingelmaier A, Schindlbeck C, Willgeroth F, Sommer H, Jeschke U, Friese K, Mylonas I (2007) Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur J Cancer 43:2434–2444. doi:10.​1016/​j.​ejca.​2007.​08.​014 PubMedCrossRef
29.
Zurück zum Zitat Mylonas I, Worbs S, Shabani N, Kuhn C, Kunze S, Schulze S, Dian D, Gingelmaier A, Schindlbeck C, Bruning A, Sommer H, Jeschke U, Friese K (2009) Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur J Cancer 45:1304–1314. doi:10.1016/j.ejca.2009.01.008 PubMedCrossRef Mylonas I, Worbs S, Shabani N, Kuhn C, Kunze S, Schulze S, Dian D, Gingelmaier A, Schindlbeck C, Bruning A, Sommer H, Jeschke U, Friese K (2009) Inhibin-alpha subunit is an independent prognostic parameter in human endometrial carcinomas: analysis of inhibin/activin-alpha, -betaA and -betaB subunits in 302 cases. Eur J Cancer 45:1304–1314. doi:10.​1016/​j.​ejca.​2009.​01.​008 PubMedCrossRef
30.
Zurück zum Zitat Käufl SD, Kuhn C, Kunze S, Shabani N, Bruning A, Friese K, Mylonas I (2010) Inhibin/activin-betaC subunit does not represent a prognostic parameter in human endometrial cancer. Arch Gynecol Obstet. doi:10.1007/s00404-010-1614-y Käufl SD, Kuhn C, Kunze S, Shabani N, Bruning A, Friese K, Mylonas I (2010) Inhibin/activin-betaC subunit does not represent a prognostic parameter in human endometrial cancer. Arch Gynecol Obstet. doi:10.​1007/​s00404-010-1614-y
31.
Zurück zum Zitat Mylonas I (2010) Inhibin-betaA subunit immunolabeling as a prognostic factor in endometrioid adenocarcinomas: a matter of evaluation? Arch Gynecol Obstet. doi:10.1007/s00404-010-1680-1 Mylonas I (2010) Inhibin-betaA subunit immunolabeling as a prognostic factor in endometrioid adenocarcinomas: a matter of evaluation? Arch Gynecol Obstet. doi:10.​1007/​s00404-010-1680-1
32.
Zurück zum Zitat Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef
33.
Zurück zum Zitat Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187–220 Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187–220
34.
Zurück zum Zitat Mylonas I, Matsingou C, Käufl SD, Brüning A (2011) Inhibin/activin betaE-subunit in uterine endometrioid adenocarcinoma and endometrial cancer cell lines: From immunohistochemistry to clinical testing? Gynecol Oncol. doi:10.1016/j.ygyno.2011.03.019 Mylonas I, Matsingou C, Käufl SD, Brüning A (2011) Inhibin/activin betaE-subunit in uterine endometrioid adenocarcinoma and endometrial cancer cell lines: From immunohistochemistry to clinical testing? Gynecol Oncol. doi:10.​1016/​j.​ygyno.​2011.​03.​019
35.
Zurück zum Zitat Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40:55–65PubMedCrossRef Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40:55–65PubMedCrossRef
36.
Zurück zum Zitat Barakat RR, Lev G, Hummer AJ, Sonoda Y, Chi DS, Alektiar KM, Abu-Rustum NR (2007) Twelve-year experience in the management of endometrial cancer: a change in surgical and postoperative radiation approaches. Gynecol Oncol 105:150–156. doi:10.1016/j.ygyno.2006.11.007 PubMedCrossRef Barakat RR, Lev G, Hummer AJ, Sonoda Y, Chi DS, Alektiar KM, Abu-Rustum NR (2007) Twelve-year experience in the management of endometrial cancer: a change in surgical and postoperative radiation approaches. Gynecol Oncol 105:150–156. doi:10.​1016/​j.​ygyno.​2006.​11.​007 PubMedCrossRef
39.
Zurück zum Zitat Seracchioli R, Solfrini S, Mabrouk M, Facchini C, Di Donato N, Manuzzi L, Savelli L, Venturoli S (2010) Controversies in surgical staging of endometrial cancer. Obstet Gynecol Int 2010:181963. doi:10.1155/2010/181963 PubMed Seracchioli R, Solfrini S, Mabrouk M, Facchini C, Di Donato N, Manuzzi L, Savelli L, Venturoli S (2010) Controversies in surgical staging of endometrial cancer. Obstet Gynecol Int 2010:181963. doi:10.​1155/​2010/​181963 PubMed
41.
Zurück zum Zitat Vorgias G, Fotiou S (2010) The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature review. Arch Gynecol Obstet doi:10.1007/s00404-010-1649-0 Vorgias G, Fotiou S (2010) The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed mullerian tumours): a critical literature review. Arch Gynecol Obstet doi:10.​1007/​s00404-010-1649-0
42.
Zurück zum Zitat Yabushita H, Shimazu M, Yamada H, Sawaguchi K, Noguchi M, Nakanishi M, Kawai M (2001) Occult lymph node metastases detected by cytokeratin immunohistochemistry predict recurrence in node-negative endometrial cancer. Gynecol Oncol 80:139–144PubMedCrossRef Yabushita H, Shimazu M, Yamada H, Sawaguchi K, Noguchi M, Nakanishi M, Kawai M (2001) Occult lymph node metastases detected by cytokeratin immunohistochemistry predict recurrence in node-negative endometrial cancer. Gynecol Oncol 80:139–144PubMedCrossRef
43.
Zurück zum Zitat Gonzalez Bosquet J, Keeney GL, Mariani A, Webb MJ, Cliby WA (2003) Cytokeratin staining of resected lymph nodes may improve the sensitivity of surgical staging for endometrial cancer. Gynecol Oncol 91:518–525PubMedCrossRef Gonzalez Bosquet J, Keeney GL, Mariani A, Webb MJ, Cliby WA (2003) Cytokeratin staining of resected lymph nodes may improve the sensitivity of surgical staging for endometrial cancer. Gynecol Oncol 91:518–525PubMedCrossRef
44.
45.
Zurück zum Zitat Chang SJ, Kim WY, Yoon JH, Yoo SC, Chang KH, Ryu HS (2008) Para-aortic lymphadenectomy improves survival in patients with intermediate to high-risk endometrial carcinoma. Acta Obstet Gynecol Scand 87:1361–1369. doi:10.1080/00016340802503054 PubMedCrossRef Chang SJ, Kim WY, Yoon JH, Yoo SC, Chang KH, Ryu HS (2008) Para-aortic lymphadenectomy improves survival in patients with intermediate to high-risk endometrial carcinoma. Acta Obstet Gynecol Scand 87:1361–1369. doi:10.​1080/​0001634080250305​4 PubMedCrossRef
46.
47.
Zurück zum Zitat Yoon JH, Yoo SC, Kim WY, Chang SJ, Chang KH, Ryu HS (2010) Para-aortic Lymphadenectomy in the Management of Preoperative Grade 1 Endometrial Cancer Confined to the Uterine Corpus. Ann Surg Oncol. doi:10.1245/s10434-010-1199-5 Yoon JH, Yoo SC, Kim WY, Chang SJ, Chang KH, Ryu HS (2010) Para-aortic Lymphadenectomy in the Management of Preoperative Grade 1 Endometrial Cancer Confined to the Uterine Corpus. Ann Surg Oncol. doi:10.​1245/​s10434-010-1199-5
Metadaten
Titel
Lymphadenectomy as a prognostic marker in uterine non-endometrioid carcinoma
verfasst von
Ioannis Mylonas
Christian Schindlbeck
Publikationsdatum
01.01.2012
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 1/2012
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-011-1914-x

Weitere Artikel der Ausgabe 1/2012

Archives of Gynecology and Obstetrics 1/2012 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.